What are the current adult gastroenterology guidelines for screening, diagnosis, and management of colorectal cancer, gastro‑oesophageal reflux disease, Helicobacter pylori infection, irritable bowel syndrome, inflammatory bowel disease, non‑alcoholic fatty liver disease, esophageal varices, and peptic ulcer disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Adult Gastroenterology Guidelines: Comprehensive Management Overview

Colorectal Cancer Screening

Begin colorectal cancer screening at age 45 years for all average-risk adults, continuing through age 75 years, with individualized decisions for ages 76-85 years and cessation after age 85 years. 1, 2

Screening Strategy by Age Group:

  • Ages 45-49 years: Conditional recommendation to begin screening (American College of Gastroenterology 2021) 1
  • Ages 50-75 years: Strong recommendation for routine screening across all major guidelines 1, 2
  • Ages 76-85 years: Individualize based on patient health status, prior screening history, and life expectancy 1
  • Age >85 years: Stop screening 1

Recommended Screening Modalities:

First-line options include:

  • Colonoscopy every 10 years (preferred method) 2
  • Annual fecal immunochemical test (FIT) 1, 2
  • Flexible sigmoidoscopy every 5 years 1
  • Stool DNA-FIT (e.g., Cologuard) - though direct mortality benefit data remain limited 1

Special Populations:

Black adults: Consider screening at age 45 years given higher incidence and mortality rates, though this represents a weak recommendation pending more research on contributing factors 1

Family history: Begin screening at age 40 years OR 10 years before the youngest affected family member's diagnosis age, whichever comes earlier 1

Critical Pitfall:

The evidence shows that adherence to screening intervals is crucial - repeated colonoscopy at 10 years or annual stool testing significantly impacts overall program effectiveness. Any screening is better than none, so patient preference should guide modality selection to maximize adherence 1.

Inflammatory Bowel Disease (IBD)

Colorectal Cancer Surveillance in IBD

Patients with colonic IBD require structured colonoscopic surveillance beginning 8-10 years after symptom onset, with intervals determined by multivariate risk stratification rather than fixed time periods. 3

Key surveillance principles:

  • Use web-based multivariate risk calculators to determine individualized surveillance intervals 3
  • Employ high-definition white light endoscopy as the minimum standard 3
  • Ensure adequate bowel preparation (Boston Bowel Preparation Scale ≥6 with all segments ≥2) 3
  • Perform surveillance during disease remission when possible 3

Management of Active IBD

For jejunal or extensive small bowel Crohn's disease, consider early biological therapy (anti-TNF agents) given the poorer prognosis, higher stricture rates, and increased surgical recurrence risk. 4

Upper GI Crohn's disease management algorithm:

  1. Mild oesophageal disease: Proton pump inhibitors first-line 4
  2. Worsening symptoms: Short-course corticosteroids 4
  3. Moderate-severe or refractory disease: Early anti-TNF therapy 4
  4. Strictures: Endoscopic balloon dilatation 4
  5. All patients: Mandatory nutritional assessment and support 4

Critical caveat: Always exclude and eradicate Helicobacter pylori in upper GI Crohn's disease before escalating therapy 4. Consider alternative diagnoses in isolated oesophageal disease including GERD, sarcoidosis, tuberculosis, fungal infections, Behçet's disease, and malignancy 4.

Leucocyte apheresis should NOT be used for active Crohn's disease due to lack of efficacy (strong recommendation) 4.

Helicobacter pylori Infection

For treatment-naïve H. pylori infection, bismuth quadruple therapy (BQT) for 14 days is the preferred empiric regimen when antibiotic susceptibility is unknown. 5

First-Line Treatment Options:

Preferred: Bismuth quadruple therapy × 14 days (PPI + bismuth + tetracycline + metronidazole) 5

Suitable alternatives (in patients without penicillin allergy):

  • Rifabutin triple therapy × 14 days 5
  • Potassium-competitive acid blocker (P-CAB) dual therapy × 14 days 5

Salvage Therapy for Treatment Failure:

For patients who fail initial therapy:

  • If NOT previously treated with optimized BQT: Use optimized BQT × 14 days 5
  • If previously treated with optimized BQT: Rifabutin triple therapy × 14 days 5

Critical restriction: Clarithromycin- or levofloxacin-containing regimens should only be used for salvage if antibiotic susceptibility is confirmed by testing 5

Post-Treatment Management:

Universal test-of-cure is recommended for all patients following H. pylori treatment to confirm eradication 5

Clinical Context:

H. pylori causes peptic ulcer disease and gastric cancer, making eradication essential 5, 6. However, eradication does not always alleviate dyspeptic symptoms, so patients should be counseled accordingly 6. The recent data show no robust causal relationship between H. pylori or peptic ulcer disease and colorectal cancer risk in European populations, though some association exists in East Asian populations 7.

Gastroesophageal Reflux Disease (GERD)

Proton pump inhibitors (PPIs) are first-line medication for GERD, with H2-receptor antagonists as second-line therapy. 6

Treatment Algorithm:

  1. First-line: PPI therapy (standard or double-dose depending on severity) 6
  2. Second-line: H2-receptor antagonists if PPIs inadequate or not tolerated 6
  3. Refractory cases: Consider alternative diagnoses, compliance issues, or need for endoscopic evaluation 6

Important distinction: In Crohn's disease patients with upper GI involvement, PPIs serve as first-line therapy for mild oesophageal disease specifically, but escalation to immunosuppression may be needed for true inflammatory disease 4.

Peptic Ulcer Disease (PUD)

Management centers on H. pylori eradication when present, with PPI therapy as the cornerstone of ulcer healing. 5, 6

Management Approach:

  1. Test for H. pylori in all PUD patients 5
  2. Eradicate if positive using BQT × 14 days as preferred regimen 5
  3. PPI therapy for ulcer healing (duration depends on ulcer size and complications) 6
  4. Confirm eradication with test-of-cure 5

Key point: While H. pylori eradication reduces gastric ulcer and cancer risk, it may not always resolve dyspeptic symptoms 6. The causal relationship between PUD and colorectal cancer appears ancestry-specific, with significance in East Asian but not European populations 7.

Irritable Bowel Syndrome (IBS)

The provided evidence does not contain specific IBS management guidelines. Based on general gastroenterology knowledge, diagnosis requires Rome IV criteria (recurrent abdominal pain ≥1 day/week for 3 months associated with defecation changes and/or stool frequency/form changes), with management including dietary modification (low FODMAP diet), pharmacotherapy based on predominant subtype (IBS-D, IBS-C, IBS-M), and consideration of gut-directed psychotherapy for refractory cases.

Non-Alcoholic Fatty Liver Disease (NAFLD)

The provided evidence does not contain specific NAFLD management guidelines. This represents a significant evidence gap requiring consultation of dedicated hepatology guidelines.

Esophageal Varices

The provided evidence does not contain specific guidelines for esophageal varices screening or management. This requires consultation of dedicated hepatology and portal hypertension guidelines.

Quality Indicators and Service Delivery

For IBD surveillance colonoscopy, specific outcome standards should guide service and endoscopist audit, with emphasis on:

  • Adequate bowel preparation 3
  • Complete examination during remission 3
  • Use of high-definition equipment 3
  • Shared decision-making with patients 3
  • Consideration of artificial intelligence-aided detection technologies 3

For colorectal cancer screening programs:

  • Monitor and improve adherence rates across all modalities 2
  • Implement organized screening programs with systematic recall 2
  • Remove barriers throughout the care spectrum from screening to diagnostic colonoscopy 2
  • Track quality metrics including adenoma detection rates 2

References

2
Research

ACG Clinical Guidelines: Colorectal Cancer Screening 2021.

The American journal of gastroenterology, 2021

5
Research

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

The American journal of gastroenterology, 2024

Related Questions

What are the current adult guidelines for colorectal cancer screening, gastro‑esophageal reflux disease treatment, Helicobacter pylori‑associated peptic ulcer disease, irritable bowel syndrome management, and inflammatory bowel disease therapy?
What are the guidelines for routine colonoscopy screening in individuals over age 50, and how do they differ for those with no family history of colorectal cancer?
In an 85-year-old patient with chest pain localized to the same spot that worsens when lying supine and a history of peptic ulcer disease, what is the differential diagnosis and appropriate management plan?
In a 72-year-old man with six months of epigastric pain and a sensation of gastric fullness, normal upper gastrointestinal endoscopy, negative Helicobacter pylori testing, and no weight loss or iron‑deficiency anemia, which of the following is NOT appropriate: A) Empiric proton‑pump inhibitor therapy, B) Treatment with tricyclic antidepressants or metoclopramide‑type prokinetics, C) Empiric Helicobacter pylori eradication therapy, D) Empiric therapy with non‑absorbable antibiotics such as rifaximin, E) Avoidance of alcohol, caffeine, and smoking?
For a 45-year-old male with newly diagnosed Helicobacter pylori infection, type 2 diabetes mellitus, hypertension, currently taking lisinopril and metformin, and without antibiotic susceptibility data, which first‑line regimen recommended by the 2024 American College of Gastroenterology guideline is most appropriate: clarithromycin‑based triple therapy (proton‑pump inhibitor + clarithromycin + amoxicillin), rifabutin‑based triple therapy (proton‑pump inhibitor + rifabutin + amoxicillin), vonoprazan‑based dual therapy (vonoprazan + amoxicillin), or optimized bismuth quadruple therapy (proton‑pump inhibitor + bismuth subcitrate + tetracycline + metronidazole)?
What is bronchospasm?
What oxytocin dose should be given to an adult intact female dog in active labor after fetal membrane rupture?
What is the likelihood of having two consecutive miscarriages?
Does prostate massage worsen prostate cancer symptoms or promote tumor growth?
Is altitude-related pulmonary hypertension reversible with descent to lower altitude or supplemental oxygen?
What are the current guidelines for evaluating and managing gastrointestinal disorders, including acute abdominal pain, chronic symptoms, irritable bowel syndrome, inflammatory bowel disease, and liver disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.